LENZ Therapeutics (LENZ) Interest Expenses (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Interest Expenses of $716000.0 for Q1 2026, down 44.88% year-over-year from $1.3 million in Q1 2025, and up 2457.14% quarter-over-quarter from $28000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Interest Expenses (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Interest Expenses for 7 consecutive years, with $716000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 44.88% year-over-year to $716000.0; the TTM figure through Mar 2026 stood at $716000.0 (down 44.88% YoY), while the FY2025 annual figure was $70.3 million, up 26.6% from the prior year.
- Interest Expenses rose to $716000.0 in Q1 2026 per LENZ's latest filing, from $28000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $608.9 million in Q2 2022 and bottomed at -$4.6 million in Q4 2023.
- Historically, Interest Expenses has averaged $41.0 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2023 — Interest Expenses slumped 315.45% — and 2025, when it surged 3068.29%.
- LENZ Therapeutics' Interest Expenses stood at $2.1 million in 2022, then plunged by 315.45% to -$4.6 million in 2023, then surged by 138.88% to $1.8 million in 2024, then slumped by 98.44% to $28000.0 in 2025, then soared by 2457.14% to $716000.0 in 2026.
- Business Quant data shows LENZ's Interest Expenses at $716000.0 in Q1 2026, $28000.0 in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 640,000.00 |
| Jun 30, 2026 | 640,000.00 |
| Mar 31, 2026 | 716,000.00 |
| Mar 31, 2026 | 716,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Sep 30, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 41,000.00 |
| Mar 31, 2024 | 41,000.00 |